Enalapril (Envas) in the Postpartum Period
Enalapril is safe and recommended as a first-line antihypertensive agent for postpartum hypertension, including in breastfeeding women with term, healthy infants. 1, 2
Key Recommendations
For All Postpartum Women with Hypertension
Enalapril is explicitly listed as a first-line agent for postpartum hypertension regardless of breastfeeding status, alongside nifedipine, amlodipine, and labetalol 1. The major advantage of enalapril is once-daily dosing, which improves adherence and aligns with standard hypertension guidelines 1.
For Breastfeeding Mothers
Enalapril is specifically recommended as the most widely used ACE inhibitor during lactation due to its safety profile and favorable pharmacokinetics 2. Multiple guidelines consistently identify enalapril as safe for breastfeeding mothers 2, 3.
Critical caveat: ACE inhibitors like enalapril should not be used if the neonate is premature or has renal failure 2. For term, healthy infants, enalapril poses minimal risk.
Evidence Supporting Safety in Lactation
Recent pharmacokinetic data demonstrates very low transfer of enalapril into breast milk:
- Milk concentrations: 0.01-1.22 ng/mL for enalapril and 0.32-0.77 ng/mL for enalaprilat (active metabolite) 4
- Relative infant dose (RID): only 0.073-0.097% - well below the 10% safety threshold 4
- Infant plasma concentrations were undetectable 4
This provides strong reassurance that breastfed infants receive negligible exposure to enalapril.
Comparative Effectiveness
While enalapril is guideline-recommended, recent comparative data shows:
- In one RCT, enalapril was not superior to nifedipine for preventing postpartum healthcare utilization (readmissions, unplanned visits) 5
- A 2026 meta-analysis found that patients on enalapril required additional antihypertensives more frequently compared to nifedipine 6
- However, small trials suggest enalapril may promote cardiac reverse remodeling in postpartum cardiomyopathy 7
Practical Algorithm for Use
Start enalapril 5-10 mg once daily if:
- Postpartum hypertension requiring treatment (BP ≥150/100 mmHg persistently, or ≥140/90 mmHg with symptoms/end-organ effects)
- Infant is term and healthy (no prematurity, no renal dysfunction)
- Patient prefers once-daily dosing or has peripartum cardiomyopathy
Choose nifedipine or amlodipine instead if:
- Neonate is premature or has renal issues
- Patient needs more rapid BP control (nifedipine acts faster)
- Real-world data suggests nifedipine may reduce readmission rates slightly 7
Avoid labetalol as first choice - requires twice-daily or more frequent dosing and recent data shows it may be less effective postpartum with higher readmission risk compared to calcium channel blockers 1, 7.
Treatment Targets and Duration
- Target BP: ≤140/90 mmHg in clinic (approximately ≤135/85 mmHg at home) 7
- Urgent treatment threshold: ≥160/110 mmHg (use IV labetalol/hydralazine or oral immediate-release nifedipine if no IV access) 7
- Continue antihypertensive until BP normalizes, which may take days to several weeks postpartum 2
- Early follow-up within 3-10 days (within 72 hours if severe disease) 7
Special Consideration: Peripartum Cardiomyopathy
Enalapril may be particularly suitable for peripartum cardiomyopathy treatment 2, as ACE inhibitors are standard heart failure therapy. If mild reduction in ejection fraction (40-50%) is present with hypertensive disorders of pregnancy, adopting heart failure guidelines with combination therapy including enalapril is reasonable 1.
Common Pitfalls to Avoid
- Do not use enalapril during pregnancy - ACE inhibitors are strictly contraindicated antepartum due to teratogenicity 3
- Do not use in premature or renally impaired neonates during breastfeeding 2
- Do not rely on enalapril alone if BP remains uncontrolled - add a second agent (typically nifedipine or amlodipine) rather than maximizing enalapril dose 6
- Avoid diuretics as monotherapy - they may reduce milk production at higher doses 1, 2